natgillin/translations-raw huggingface dataset:
Patienter, der tager Ranexa, skal have udleveret et særligt informationskort, der sammenfatter de vigtigste sikkerhedsoplysninger om lægemidlet.
Patients who take Ranexa must be given a ‘patient alert card’ that summarises the key safety information on the medicine.
Patienter, der tager Renvela skal overholde den ordinerede diæt.
Patients taking Renvela should adhere to their prescribed diets.
Patienter, der tager Renvela, skal overholde den ordinerede diæt.
Patients taking Renvela should adhere to their prescribed diets.
Patienter, der tager rifampicin (et antibiotikum), kan være nødt til at tage en højere dosis af Stocrin.
Patients taking rifampicin (an antibiotic) may need to take a higher dose of Stocrin.
Patienter, der tager rifampicin (et antibiotikum), kan være nødt til at tage en højere dosis af Sustiva.
Patients taking rifampicin (an antibiotic) may need to take a higher dose of Sustiva.
Patienter, der tager Sevelamer carbonate Zentiva skal overholde den ordinerede diæt.
Patients taking Sevelamer carbonate Zentiva should adhere to their prescribed diets.
Patienter, der tager Sevelamer carbonate Zentiva, skal overholde den ordinerede diæt.
Patients taking Sevelamer carbonate Zentiva should adhere to their prescribed diets.
Patienter, der tager tenofovir, hvis REYATAZ/ritonavir administreres samtidigt med både tenofovirdisoproxilfumarat og en H2-receptorantagonist, anbefales dosisøgning af REYATAZ til 400 mg med 100 mg ritonavir.
For patients who are taking tenofovir, if REYATAZ/ritonavir with both tenofovir and an H2-receptor antagonist are co-administered,a dose increase of REYATAZ to 400 mg with 100 mg of ritonavir is recommended.
Patienter, der tager Volibris, skal have målt deres hæmoglobin og/eller hæmatokrit regelmæssigt.
Patients taking Volibris should have their haemoglobin and/or haematocrit levels measured regularly.
Patienter, der tager Xyrem, bør holde op med at amme.
Patients taking Xyrem should stop breast feeding.
Patienter, der tager østrogener
Patients using oestrogens
Patienter, der tidligere blev behandlet med DMARDs eller biologiske midler, og som fik apremilast, opnåede et større ACR 20- respons efter uge 16 end patienterne, der fik placebo.
Patients previously treated with DMARDs or biologics who received apremilast achieved a greater ACR 20 response at Week 16 than patients receiving placebo.
Patienter, der tidligere er behandlet med immunglobulin administreret intravenøst
Patients previously treated with immunoglobulin administered intravenously
Patienter, der tidligere er behandlet med immunglobulin administreret subkutant
Patients previously treated with immunoglobulin administered subcutaneously
Patienter, der tidligere er blevet behandlet med antracykliner
Anthracycline pre-treated patients
Patienter, der tidligere har fået behandling mod avanceret eller metastatisk brystkræft, skal tage Tyverb i kombination med capecitabin.
Tyverb is prescribed in combination with capecitabine, for patients who have had treatment for advanced or metastatic breast cancer before.
Patienter, der tidligere har fået omfattende myelosuppressiv kemoterapi, vil ikke altid opnå tilstrækkelig mobilisering af PBPC til at nå det anbefalede minimumsresultat (2,0 x 106 CD34+ celler/kg) eller acceleration i gendannelsen af trombocytter i samme omfang.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Patienter, der tidligere har haft intrakraniel blødning (ICH).
Patients with a history of intracranial haemorrhage (ICH).
Patienter, der tidligere har seponeret behandlingen med tenofovirdisoproxilfumarat på grund af nyretoksicitet, med eller uden ophør af nyrepåvirkningen efter seponering, bør ikke behandles med Stribild (se pkt.
Patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity, with or without reversal of the effects post-discontinuation, should not be treated with Stribild (see section 4.3).
Patienter, der tidligere har seponeret behandlingen med tenofovirdisoproxilfumarat på grund af nyretoksicitet, med eller uden ophør af nyrepåvirkningen efter seponering.
Patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity, with or without reversal of the effects post-discontinuation.
Patienter, der tidligere har taget phosphatbindere (baseret på sevelamer hydrochlorid eller kalcium), bør indgives Renvela på gram til gram basis under overvågning af serumphosphatniveauet for at sikre en optimal daglig dosis.
For patients previously on phosphate binders (sevelamer hydrochloride or calcium based), Renvela should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.
Patienter, der tidligere har taget phosphatbindere (eller kalcium), bør indgives Renvela på gram til gram basis under overvågning af serumphosphatniveauet for at sikre en optimal daglig dosis.
For patients previously on phosphate binders (sevelamer hydrochloride or calcium based), Renvela should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.
Patienter, der tidligere har taget phosphatbindere (sevelamerhydrochlorid eller kalciumbaseret), bør indgives Sevelamer carbonate Zentiva på gram til gram basis under overvågning af serumphosphatniveauet for at sikre en optimal daglig dosis.
For patients previously on phosphate binders (sevelamer hydrochloride or calcium based), Sevelamer carbonate Zentiva should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.
Patienter, der tidligere har udført selv- mordsrelaterede handlinger, eller patienter, der før behandlingsstart har udvist en signifikant grad af selvmordsforestillinger, har en større risiko for selvmordstanker eller selvmordsadfærd og bør følges nøje under behandlingen.
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at a greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment.
Patienter, der tidligere har udført selvmords- relaterede handlinger, eller patienter, der før behandlingsstart har udvist en signifikant grad af selv- mordsforestillinger, har en større risiko for selvmordstanker eller selvmordsadfærd og bør følges nøje under behandlingen.
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment.
Patienter, der tidligere har udført selvmordsrelaterede handlinger, eller patienter, der før behandlingsstart har udvist en signifikant grad af selvmords- forestillinger, har en større risiko for selvmordstanker eller selvmordsadfærd og bør følges nøje under behandlingen.
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment.
Patienter, der tidligere har vist overfølsomhed over for cefalosporiner, penicilliner eller andre beta- laktamantibiotika, kan også være overfølsomme over for ceftarolinfosamil.
Patients who have a history of hypersensitivity to cephalosporins, penicillins or other beta-lactam antibacterials may also be hypersensitive to ceftaroline fosamil.
Patienter, der tidligere har været behandlet med BRAF-hæmmer
Prior BRAF inhibitor therapy
Patienter, der tidligere har været behandlet med PI’er Amprenavir
PI-experienced patients Amprenavir
Patienter, der tidligere har været behandlet uden terapeutisk effekt
Previously treatment failure patients
Patienter, der tidligere har været i behandling med andre fosfatbindere, og som skifter til Fexeric, skal starte med at tage 3 til 6 g (3 til 6 tabletter) om dagen.
Patients previously on other phosphate binders who are switched to Fexeric should start taking 3 to 6 g (3 to 6 tablets) per day.
Patienter, der tidligere var insulinnaive eller på basalinsulin
Patients previously Insulin naive or on basal isnulin
Patienter, der tidligerehar fået omfattende myelosuppressiv kemoterapi, vil ikke altid opnå tilstrækkelig mobilisering af PBPC til at nå det anbefalede minimumsresultat (2,0 x 106 CD34+ celler/kg) eller acceleration i gendannelsen af trombocytter i samme omfang.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Patienter, der tog Caprelsa, levede i gennemsnit i 30,5 måneder uden forværring af deres sygdom, sammenlignet med 19,3 måneder for de patienter, der tog placebo.
On average, patients taking Caprelsa lived for 30.5 months without their disease getting worse, compared with 19.3 months for patients taking placebo.
Patienter, der tog Ilaris i del II, havde 64 % reduceret risiko for udbrud sammenlignet med placebogruppen (hazard ratio 0,36; 95 % konfidensinterval: 0,17 til 0,75; p=0,0032).
Patients taking Ilaris in part II had a 64% reduced risk of a flare event as compared to the placebo group (hazard ratio of 0.36; 95% CI: 0.17 to 0.75; p=0.0032).
Patienter, der tog Instanyl, fik lov til at tage endnu et pust 10 minutter efter den første dosis, hvis smertelindringen ikke var tilstrækkelig.
The patients taking Instanyl were allowed to take a second spray ten minutes after the first dose if there had been insufficient pain relief.
Patienter, der udviklede anti-alemtuzumab-antistoffer, gjorde dette inden for 15 måneder efter den første eksponering.
Patients who developed anti-alemtuzumab antibodies did so by 15 months from initial exposure.
Patienter, der udviklede antistoffer over for exenatid, var tilbøjelige til at have flere reaktioner på injektionsstedet (f.eks. hudrødme og kløe), men havde ellers lignende hyppigheder og typer af bivirkninger som dem, der ikke udviklede exenatid-antistoffer.
Patients who develop antibodies to exenatide tend to have more injection site reactions (for example: redness of skin and itching), but otherwise similar rates and types of adverse events as those with no anti- exenatide antibodies.
Patienter, der udvikler anæmi under eller efter behandlingen med Zinforo, bør derfor undersøges for denne risiko.
Patients experiencing anaemia during or after treatment with Zinforo should be investigated for this possibility.
Patienter, der udvikler en ny infektion under behandling med Humira, bør monitoreres nøje og gennemgå en fuldstænding diagnostisk evaluering.
Patients who develop a new infection while undergoing treatment with Humira, should be monitored closely and undergo a complete diagnostic evaluation.
Patienter, der udvikler gulsot eller andre symptomer, som tyder på leverdysfunktion, bør ophøre behandling med Icandra.
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Icandra.
Patienter, der udvikler inhibitoriske antistoffer over for OBIZUR
Patients developing inhibitory antibodies to OBIZUR
Patienter, der udvikler stigninger i aminotransferase-niveauer, bør monitoreres nøje, indtil niveauerne ikke længere er unormale.
Patients who develop increased transaminase levels should be monitored closely until the abnormalities resolve.
Patienter, der udvikler symptomer på arytmi eller ny forekomst af dyspnø, skal evalueres klinisk, og der skal tages et elektrokardiogram (EKG) på klinisk indikation.
Patients who develop arrhythmic symptoms or new onset of dyspnoea should be evaluated clinically and if indicated have an electrocardiogram (ECG) performed.
Patienter, der udviser depression, bør monitoreres nøje under behandling med Betaferon og behandles hensigtsmæssigt.
Patients exhibiting depression should be monitored closely during therapy with Betaferon and treated appropriately.
Patienter, der udviste et pædiatrisk ACR 30-respons ved uge 16, var egnede til randomisering i den dobbeltblindede fase og fik enten Humira 24 mg/m2 op til maksimalt 40 mg eller placebo hver anden uge i yderligere 32 uger eller indtil opblussen af sygdommen.
Patients demonstrating a Pediatric ACR 30 response at Week 16 were eligible to be randomised into the double blind (DB) phase and received either Humira 24 mg/m2 up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare.
Patienter, der udviste pædiatrisk ACR 30-respons ved uge 16, var egnede til randomisering i den dobbeltblindede fase og fik enten Humira 24 mg/m2 op til maksimalt 40 mg eller placebo hver anden uge i yderligere 32 uger eller indtil opblussen af sygdommen.
Patients demonstrating a Pediatric ACR 30 response at Week 16 were eligible to be randomised into the double blind (DB) phase and received either Humira 24 mg/m2 up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare.
Patienter, der undergår større operationer, kan behandles i op til 2-3 uger, indtil heling er opnået.
Patients undergoing major surgery may be treated for up to 2 – 3 weeks until healing has occurred.
Patienter, der utilsigtet har fået for meget Thyrogen, har indberettet kvalme, svaghed, svimmelhed, hovedpine, opkastning og hedeture.
Patients who accidentally received too much Thyrogen have reported nausea, weakness, dizziness, headache, vomiting and hot flashes.
Patienter, der var blevet behandlet med Simponi, oplevede signifikant flere forbedringer i helbredsrelateret livskvalitet, vurderet ved ASQoL, EQ-5D samt fysiske og mentale komponenter af SF-36, og oplevede signifikant flere forbedringer i ydeevne vurderet ved større forbedring i nedsat arbejdsevne totalt set og i nedsat aktivitetsniveau vurderet ved WPAI-spørgeskemaet end patienter, der fik placebo.
Simponi treatment resulted in significant improvement in physical function as assessed by HAQ DI, as well as significant improvements in health-related quality of life as measured by the physical and mental component summary scores of the SF-36.
Patienter, der var co-inficeret med hepatitis B- og/eller C-virus, fik mulighed for at blive inkluderet i fase III- studier, forudsat at resultaterne af deres leverkemianalyser ved baseline ikke oversteg 5 gange den øvre normalgrænse (ULN).
In Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
Patienter, der var involveret i dette studie, havde en MMSE-score (Mini-Mental State Examination) på 10 – 24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10 – 24.
Patienter, der var involveret i dette studie, havde en MMSE-score (Mini-Mental State Examination) på 10–24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10 – 24.
Patienter, der var involveret i dette studie, havde en MMSE-score (Mini-Mental State Examination) på 10–24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24.
Patienter, der var involveret i dette studie, havde en MMSE-score (Mini-Mental State Examination) på 10–24.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10–24.
Patienter, der var randomiseret til Cosentyx, fik 10 mg/kg intravenøst ved uge 0, 2 og 4 efterfulgt af enten 75 mg eller 150 mg subkutant hver måned begyndende ved uge 8.
Patients randomised to Cosentyx received 10 mg/kg intravenously at Weeks 0, 2, and 4, followed by either 75 mg or 150 mg subcutaneously every month starting at Week 8.
Patienter, der var randomiseret til Cosentyx, fik 75 mg eller 150 mg subkutant ved uge 0, 1, 2 og 3 efterfulgt af samme dosis hver måned begyndende ved uge 4.
Patients randomised to Cosentyx received 75 mg or 150 mg subcutaneously at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Patienter, der var randomiseret til Cosentyx, fik 75 mg, 150 mg eller 300 mg subkutant ved uge 0, 1, 2 og 3 efterfulgt af samme dosis hver måned begyndende ved uge 4.
Patients randomised to Cosentyx received 75 mg, 150 mg or 300 mg subcutaneously at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Patienter, der var randomiseret til Cosentyx, fik doser på 150 mg eller 300 mg i ugerne 0, 1, 2 og 3, fulgt af samme dosis hver måned med start i uge 4.
Patients randomised to Cosentyx received 150 mg or 300 mg doses at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Patienter, der var randomiseret til placebo, og som havde responderet ved uge 16, blev krydset over til at få Cosentyx (enten 150 mg eller 300 mg subkutant) ved uge 24 efterfulgt af samme dosis hver måned.
Patients randomised to receive placebo who were responders at Week 16 were crossed over to receive Cosentyx (either 150 mg or 300 mg subcutaneously) at Week 24 followed by the same dose every month.
Patienter, der var randomiseret til placebo, og som ikke havde responderet ved uge 16 (tidlig erstatningsbehandling), blev krydset over til at få Cosentyx (enten 150 mg eller 300 mg subkutant) ved uge 16 efterfulgt af samme dosis hver måned.
Patients randomised to receive placebo who were non-responders at Week 16 (early rescue) were crossed over to receive Cosentyx (either 150 mg or 300 mg subcutaneously) at Week 16 followed by the same dose every month.
Patienter, der var randomiseret til placebo, og som ikke havde responderet ved uge 16 (tidlig erstatningsbehandling), blev krydset over til at få Cosentyx (enten 75 mg eller 150 mg subkutant) ved uge 16 efterfulgt af samme dosis hver måned.
Patients randomised to placebo who were non-responders at Week 16 (early rescue) and all other placebo patients at Week 24 were crossed over to receive Cosentyx (either 75 mg or 150 mg subcutaneously), followed by the same dose every month.
Patienter, der var randomiseret til placebo, og som ikke havde responderet ved uge 16 (tidlig erstatningsbehandling), blev krydset over til at få Cosentyx (enten 75 mg eller 150 mg subkutant) ved uge 16 efterfulgt af samme dosis hver måned.
Patients randomised to placebo who were non-responders at Week 16 (early rescue) and other placebo patients at Week 24 were crossed over to receive Cosentyx (either 75 mg or 150 mg subcutaneously) followed by the same dose every month.
Patienter, der var randomiseret til vPDT, måtte få behandling med ranibizumab fra måned 3 (i Gruppe III fik 38 patienter ranibizumab fra måned 3)
Patients randomised to vPDT were allowed to receive ranibizumab treatment as of Month 3 (in Group III, 38 patients received ranibizumab as of Month 3)
Patienter, der vejer 20-55 kga
Patients of weight 20 to 55 kga
Patienter, der vejer 80 kg eller derover: 100 mg (indholdet af 1 fyldt injektionssprøjte) 4 uger efter Deres sidste behandling og derefter hver 4. uge.
In patients weighing 80 kg or more, 100 mg (the contents of
Patienter, der vejer 80 kg eller derover: 100 mg (indholdet af 1 fyldt pen) 4 uger efter Deres sidste behandling og derefter hver 4. uge.
In patients weighing 80 kg or more, 100 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter.
Patienter, der vejer 80 kg eller derover: 100 mg (indholdet af 2 fyldte injektionssprøjter) 4 uger efter Deres sidste behandling og derefter hver 4. uge.
In patients weighing 80 kg or more, 100 mg (the contents of 2 pre-filled syringes) 4 weeks after your last treatment, then every 4 weeks thereafter.
Patienter, der vejer 80 kg eller derover: 100 mg (indholdet af 2 fyldte penne) 4 uger efter Deres sidste behandling og derefter hver 4. uge.
In patients weighing 80 kg or more, 100 mg (the contents of
Patienter, der vejer mere end 25 kg, skal have et samlet volumen på 250 ml.
Patients weighing 25 kg or more should receive a total volume of 250 ml.
Patienter, der vejer mindre end 25 kg, skal have et samlet volumen på 100 ml.
Patients weighing less than 25 kg should receive a total volume of 100 ml.
Patienter, der venter på levertransplantation og efter levertransplantation – SOLAR-1
Patients awaiting liver transplantation and post-liver transplant – SOLAR-1
Patienter, der venter på levertransplantation – studie 2025
Patients awaiting liver transplantation - Study 2025
Patienter, der ønsker graviditet, bør derfor enten undgå Fortacin eller – hvis penetration er vigtig for dem – vaske hovedet af penis så grundigt som muligt fem minutter efter påføring af Fortacin, men før samleje.
Therefore, patients hoping to achieve conception should either avoid using Fortacin, or, if this medicine is essential to achieve penetration, should wash the penis as thoroughly as possible five minutes after Fortacin has been applied, but prior to intercourse.
patienter, hos hvem blodsukkeret ikke kan reguleres tilfredsstillende alene ved hjælp af den største dosis metformin, patienten kan tåle
patients whose blood glucose levels are not satisfactorily controlled by the maximum tolerated dose of metformin alone;
patienter, hos hvem mere end 25 % af knoglemarven er infiltreret af lymfomceller,
> 25% of the bone marrow infiltrated by lymphoma cells
Patienter, hos hvilke brug af karkontraherende midler er kontraindiceret.
Patients with contraindications to the use of vasopressor substances.
patienter, hvis astma ikke i tilstrækkelig grad kontrolleres med et kortikosteroid- kombinationspræparat af en lavere styrke
patients not adequately controlled on a lower strength corticosteroid combination product
Patienter, hvis behandling starter med den parenterale formulering, kan skifte til den orale formulering, når det er klinisk indiceret.
Patients who commence treatment on the parenteral formulation may be switched to the oral one when clinically indicated.
Patienter, hvis blodglucosekontrol er væsentligt forbedret (f.eks. ved intensiveret behandling), kan opleve ændringer i deres sædvanlige advarselssymptomer på hypoglykæmi og skal orienteres herom.
Patients whose blood-glucose control is greatly improved (e.g. by intensified therapy) may experience a change in their usual warning symptoms of hypoglycaemia, and must be advised accordingly.
Patienter, hvis blodglucosekontrol er væsentligt forbedret (f.eks. ved intensiveret insulinbehandling), kan opleve ændringer i deres sædvanlige advarselssymptomer på hypoglykæmi og skal orienteres herom.
Patients whose blood-glucose control is greatly improved (e.g. by intensified insulin therapy) may experience a change in their usual warning symptoms of hypoglycaemia and must be advised accordingly.
Patienter, hvis blodglucosekontrol er væsentligt forbedret, f.eks ved intensiveret insulinbehandling, kan opleve ændringer i deres sædvanlige advarselssymptomer på hypoglykæmi og bør orienteres herom.
Patients whose blood glucose control is greatly improved e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.
Patienter, hvis blodsukkerkontrol er væsentligt forbedret, f.eks ved intensiveret insulinbehandling, kan opleve ændringer i deres sædvanlige advarselssymptomer på hypoglykæmi og bør orienteres herom.
Patients whose blood glucose control is greatly improved e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.
patienter, hvis brud er sygdomsrelateret (f.eks. metabolisk knoglesygdom eller kræft)
where the fracture is disease-related (such as metabolic bone disease or cancer);
Patienter, hvis diabetes allerede kontrolleres tilstrækkeligt med saxagliptin og metformin i form af separate tabletter, og som går over til Komboglyze, bør anvende den tablet, der indeholder de samme doser af hvert af indholdsstofferne.
Patients already adequately controlled with saxagliptin and metformin as separate tablets who switch to Komboglyze should use the tablet containing the same component doses.